Background Clinical responses to ipilimumab are variable in terms of onset, magnitude and
duration. Upfront identification of patients who are more likely or unlikely to benefit from …

Background: Ipilimumab improves the survival of metastatic melanoma patients. Despite
documented, durable objective responses, a significant number of patients fails to benefit …

Background There is an unmet need to identify markers predictive of response to ipilimumab
in patients with melanoma because the number of responders to ipilimumab is low and its …

Purpose: To identify baseline peripheral blood biomarkers associated with clinical outcome
following ipilimumab treatment in advanced melanoma patients. Experimental Design …

Ipilimumab produces durable responses in some metastatic melanoma patients. Neutrophil,
platelet, and eosinophil to lymphocyte ratios (NLR, PLR, and ELR) may be associated with …

Purpose: To investigate changes of peripheral blood biomarkers and their impact on clinical
outcome following treatment with ipilimumab in advanced melanoma patients. Experimental …

Abstract Background Ipilimumab (IPI) and BRAF inhibitors (BRAFi) improve survival in
melanoma, but not all patients will benefit and toxicity can be significant. Pretreatment …

Purpose: Immunotherapy with ipilimumab improves the survival of patients with metastatic
melanoma. Because only around 20% of patients experience long-term benefit, reliable …

Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio
(NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including …

Background Ipilimumab is a recently approved immunotherapy that has demonstrated an
improvement in the overall survival (OS) of patients with metastatic melanoma. We report a …